NDS Notice Board

---

NDS Notice Board

• April 11, 2019

  NDSAC Meeting of June 9-10, 2019 is cancelled

  The proposed meeting of the National Drug Scheduling Advisory Committee (NDSAC) for June 9-10, 2019 is cancelled.

• January 10, 2019

  NDSAC Meeting of March 10-11, 2019 is cancelled

  The proposed meeting of the National Drug Scheduling Advisory Committee (NDSAC) for March 10-11, 2019 is cancelled.

• November 13, 2018

  National Drug Schedules: Final Recommendations for esomeprazole 20 mg

  The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on October 11, 2018 that:

• October 22, 2018

  2019 Meeting Schedule for the National Drug Scheduling Advisory Committee (NDSAC)

  The following are the tentative meeting dates for the National Drug Scheduling Advisory Committee (NDSAC) in 2019.

• October 11, 2018

  NDSAC Interim Recommendations regarding esomeprazole 20 mg

  A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held via electronic participation from October 4-10, 2018 with the following interim recommendations made:

• October 4, 2018

  NDSAC Meeting of December 2-3, 2018 is cancelled

  The proposed meeting of the National Drug Scheduling Advisory Committee (NDSAC) for December 2-3, 2018 is cancelled.

• September 17, 2018

  NDSAC meeting of September 9, 2018

  A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on September 9, 2018 to consider the following matters:

• July 12, 2018

  National Drug Scheduling Advisory Committee Meeting September 9, 2018

  The next meeting of the National Drug Scheduling Advisory Committee (NDSAC) is scheduled for September 9, 2018. The primary purpose of the meeting is to consider the following matter:

• April 12, 2018

  NDSAC Meeting of June 10-11, 2018

  The proposed meeting of the National Drug Scheduling Advisory Committee (NDSAC) for June 10-11, 2018 is cancelled.

• March 8, 2018

  National Drug Schedules: Revisions to By-law No. 2

  The National Association of Pharmacy Regulatory Authorities recently underwent a change in governance. Subsequent to this change in governance, small changes were required to By-law No. 2, which sets out the framework for the operation of the National Drug Schedules (NDS) program.